Semaglutide Not Linked to Increased Risk of Eye Disorders, Diabetic Retinopathy
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 18, 2025 -- For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review published online Aug. 14 in JAMA Ophthalmology.
Gabriella R. Natividade, M.D., from the Universidade Federal do Rio Grande do Sul in Porto Alegre, Brazil, and colleagues examined the incidence of eye disorders, diabetic retinopathy, and nonarteritic anterior ischemic optic neuropathy (NAION) in adults treated with semaglutide in a systematic review and meta-analysis. Data were included from 78 trials with 73,640 participants.
The researchers found that the risk of eye disorders or diabetic retinopathy was not increased or reduced with semaglutide. However, semaglutide treatment was associated with a significantly increased risk of NAION (odds ratio, 3.92). The risk of bias was low overall. The sample size was sufficient to avoid missing alternative results for diabetic retinopathy but not for NAION, based on evidence provided by trial sequential analysis.
"Treatment with semaglutide in adults was not associated with an increased risk of eye disorders or diabetic retinopathy in this study, and future studies are unlikely to change these results," the authors write. "Additional studies dedicated to checking the relationship between semaglutide and NAION are needed."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
TUESDAY, Aug. 12, 2025 -- For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for...
ENDO: AI Model Integrated Into Retina Tracker IDs Diabetic Retinopathy
FRIDAY, July 18, 2025 -- An artificial intelligence (AI) model integrated into a retina tracker for diabetic retinopathy can achieve high accuracy while being resource-efficient...
Prevalence, Incidence of Diabetic Retinal Disease Increased in Recent Years
TUESDAY, July 8, 2025 -- The prevalence and incidence of diabetic retinal disease (DRD) has increased in recent years, while the incidence of vision-threatening diabetic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.